MiRNA-7 Replacement Effect on Proliferation and Tarceva-Sensitivity in U373-MG Cell Line
Related Experiment Video
Updated: Aug 17, 2026
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
Vahab Alamdari-Palangi1,2, Zahra Karami3, Hadi Karami2,4
1Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran.
Background:
Deregulation of the EGFR signaling pathway activity has been shown to can be effective in resistance to EGFR-TKIs, such as Tarceva (erlotinib), in glioblastoma cells. In addition, reports have shown that the reduction of miRNA-7 expression levels is associated with an increase in the expression of EGFR. Here, we evaluated the effect of miRNA-7 on EGFR expression and sensitivity of the U373-MG glioblastoma to erlotinib.
Methods:
The effect of miRNA-7 on EGFR expression was examined using RT-qPCR and western blotting. Trypan blue and MTT assays were performed to explore the effect of treatments on cell growth and survival, respectively. The combination index analysis was used to evaluate the interaction between drugs. Apoptosis was measured by ELISA cell death assay.
Results:
We showed that miRNA-7 markedly inhibited the expression of EGFR and decreased the growth of glioblastoma cells, relative to blank control and negative control miRNA (p < 0.05). Introduction of miRNA-7 synergistically increased the sensitivity of the U373-MG cells to erlotinib. Results of apoptosis assay demonstrated that miRNA-7 can trigger apoptosis and enhance the erlotinib-mediated apoptosis.
Conclusions:
Our results show that miRNA-7 plays a critical role in the growth, survival and sensitivity of the U373-MG cells to erlotinib by targeting EGFR. Thus, miRNA-7 replacement therapy can become an effective therapeutic procedure in glioblastoma.
Insights
MicroRNA-7 inhibits glioblastoma growth by targeting EGFR, enhancing sensitivity to erlotinib. miRNA-7 replacement therapy shows promise for glioblastoma treatment.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- EGFR signaling pathway deregulation contributes to glioblastoma resistance to EGFR-TKIs like erlotinib.
- Reduced miRNA-7 expression correlates with increased EGFR expression in glioblastoma.
Purpose of the Study:
- To investigate the effect of miRNA-7 on EGFR expression.
- To assess miRNA-7's impact on U373-MG glioblastoma cell sensitivity to erlotinib.
Main Methods:
- RT-qPCR and western blotting to analyze EGFR expression.
- Trypan blue and MTT assays for cell growth and survival.
- ELISA for apoptosis assessment.
Main Results:
- miRNA-7 significantly inhibited EGFR expression and glioblastoma cell growth.
- miRNA-7 introduction synergistically enhanced U373-MG cell sensitivity to erlotinib.
- miRNA-7 induced apoptosis and augmented erlotinib-mediated apoptosis.
Conclusions:
- miRNA-7 is crucial for glioblastoma cell growth, survival, and erlotinib sensitivity by targeting EGFR.
- miRNA-7 replacement therapy presents a potential therapeutic strategy for glioblastoma.
More Related Videos
09:45An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:22MicroRNAs